Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN359992 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Nuclear Receptor Coactivator 1 (NCOA1) (N-Term) antibody
- Antibody type
- Polyclonal
- Description
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Epitope
- N-Term
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at-20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma.
v-SRC specifically regulates the nucleo-cytoplasmic delocalization of the major isoform of TEL (ETV6).
An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1).
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness.
Hakam A, Fang Q, Karl R, Coppola D
Digestive diseases and sciences 2003 Oct;48(10):1972-8
Digestive diseases and sciences 2003 Oct;48(10):1972-8
v-SRC specifically regulates the nucleo-cytoplasmic delocalization of the major isoform of TEL (ETV6).
Lopez RG, Carron C, Ghysdael J
The Journal of biological chemistry 2003 Oct 17;278(42):41316-25
The Journal of biological chemistry 2003 Oct 17;278(42):41316-25
An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1).
Horn S, Meyer J, Stocking C, Ostertag W, Jücker M
Oncogene 2003 Oct 16;22(46):7170-80
Oncogene 2003 Oct 16;22(46):7170-80
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness.
Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE
Surgery 2003 Aug;134(2):221-6
Surgery 2003 Aug;134(2):221-6
No comments: Submit comment
No validations: Submit validation data